ALP2

Alkaline Phosphatase acc. to IFCC Gen.2

Materials provided

REF		CONTENT	Analyzer(s) on which cobas c pack(s) can be used
05166888190*	05166888500	Alkaline Phosphatase acc. to IFCC Gen.2 (1050 tests)	**cobas** c 701/702
05166888214*	05166888500	Alkaline Phosphatase acc. to IFCC Gen.2 (1050 tests)	**cobas** c 701/702

* Some kits shown may not be available in all countries.

For reagents, refer to the "Reagents" section.

Materials required (but not provided)

REF	Description	Code
10759350190	Calibrator f.a.s. (12 × 3 mL)	401
05117003190	PreciControl ClinChem Multi 1 (20 × 5 mL)	391
05947626190	PreciControl ClinChem Multi 1 (4 × 5 mL)	391
05117216190	PreciControl ClinChem Multi 2 (20 × 5 mL)	392
05947774190	PreciControl ClinChem Multi 2 (4 × 5 mL)	392
05172152190	Diluent NaCl 9 % (119 mL)	System-ID 08 6869 3
	General laboratory equipment	

System information

Short name	ACN (application code number)
ALP2L	8683

Intended use

In vitro test for the quantitative determination of alkaline phosphatase in human serum and plasma on **cobas** c systems.

Summary

Measurement of alkaline phosphatase with this assay in human serum and plasma is used to aid in the diagnosis and monitoring of liver diseases and bone diseases.

Alkaline phosphatases (EC 3.1.3.1) are membrane-bound ectoenzymes that catalyze the hydrolysis of monophosphates from ester linkage under alkaline conditions (pH 8 to 10).[1] Alkaline phosphatase isoforms are encoded by four different genes: the liver-bone-kidney (tissue-nonspecific) variant, the intestinal variant, the placental variant and the variant from the germ cells (placental-like).[1,2] Alkaline phosphatase activity is present in various tissues, but its concentration varies, and the highest concentrations are typically found in the liver and bone. Although the exact metabolic function of the enzyme is not yet understood, it appears that it is associated with lipid transport in the intestine, with the calcification process in bone, and with host defense through endotoxin dephosphorylation. Minimal amounts of intestinal alkaline phosphatase may also be present and are subjected to increase after a meal.[2]

Total serum alkaline phosphatase measurement is used extensively as a clinical indicator of liver and bone health.[1,2,3,4,5,6,7,8,9] Any form of biliary tree obstruction induces the synthesis of alkaline phosphatase by hepatocytes, therefore a rise in the alkaline phosphatase activity in serum occurs with all forms of cholestasis and particularly with obstructive jaundice.[2,3,4,5] It is also elevated in diseases of the skeletal system associated with increased osteoblastic activity, such as Paget's disease, hyperparathyroidism, rickets and osteomalacia, as well as with fractures and malignant tumors.[1,6,7,8,9,10] A physiologic rise in the alkaline phosphatase activity is sometimes seen in children and juveniles. It is caused by increased osteoblast activity following accelerated bone growth.[1,2,10]

Decreased total alkaline phosphatase activity is rarely found in human serum but can occur in hypophosphatasia, in multiple myeloma with osteolytic lesions, secondary to growth hormone deficiency or in hypoparathyroidism.[1,10]

The assay method was first described by King and Armstrong, modified by Ohmori, Bessey, Lowry and Brock and later improved by Hausamen et al.[11,12,13,14] In 2011 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division, Committee on Reference Systems of Enzymes (C-RSE) recommended a reference procedure for the determination of alkaline phosphatase using an optimized substrate concentration and 2-amino-2-methyl-1-propanol as buffer plus the cations magnesium and zinc at 37 °C.[15] This assay follows the recommendations of the IFCC, but was optimized for performance and stability.

Test principle

Reference[15]

Colorimetric assay in accordance with a standardized method.

In the presence of magnesium and zinc ions, p-nitrophenyl phosphate is cleaved by phosphatases into phosphate and p-nitrophenol.

ALP2

Alkaline Phosphatase acc. to IFCC Gen.2

p-nitrophenyl phosphate + H_2O —ALP→ phosphate + p-nitrophenol

The p-nitrophenol released is directly proportional to the catalytic ALP activity. It is determined by measuring the increase in absorbance.

Reagents

R1	2-amino-2-methyl-1-propanol: 1.724 mol/L, pH 10.44 (30 °C); magnesium acetate: 3.83 mmol/L; zinc sulfate: 0.766 mmol/L; N-(2-hydroxyethyl)-ethylenediamine triacetic acid: 3.83 mmol/L
R3	p-nitrophenyl phosphate: 132.8 mmol/L, pH 8.50 (25 °C); preservatives

R1 is in position B and R3 is in position C.

Warnings and precautions

For in vitro diagnostic use for laboratory professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste

Warning: Handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards

Apply all relevant local disposal regulations to determine safe disposal.

The Safety Data Sheet is available for professional users on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

Warning

H315	Causes skin irritation.
H319	Causes serious eye irritation.

Prevention:

P264	Wash skin thoroughly after handling.
P280	Wear protective gloves/ eye protection/ face protection.

Response:

P302 + P352	IF ON SKIN: Wash with plenty of water.
P332 + P313	If skin irritation occurs: Get medical advice/attention.
P337 + P313	If eye irritation persists: Get medical advice/attention.
P362 + P364	Take off contaminated clothing and wash it before reuse.

Product safety labeling follows EU GHS guidance.

Contact phone for all countries: +49-621-7590

Storage and stability

Shelf life at 2-8 °C	See expiration date on **cobas** c pack label.
On-board in use and refrigerated on the analyzer	4 days
On-board on the Reagent Manager	24 hours

Calibration

Calibrators	S1: H_2O S2: C.f.a.s.
Calibration mode	Linear
Calibration frequency	2-point calibration

	• after reagent lot change • as required following quality control procedures

The calibration interval may be extended based on acceptable calibration verification values determined by the laboratory.

Traceability: This method has been standardized against the IFCC procedure (2011).[15]

Quality control

For quality control, use the control materials listed in the “Materials required (but not provided)” section or other suitable control material.

Adjust the limits and control intervals based on the laboratory’s individual requirements. If values fall outside the limits, each laboratory is advised to establish corrective measures.

Follow the applicable government regulations and local guidelines.

Specimen collection and preparation

For specimen collection and preparation, only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum

Plasma: Li-heparin plasma.

Specimens derived from capillary blood were found acceptable.[16]

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing. Sample collection systems from various manufacturers may contain differing materials, which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Refer to the "Limitations and interferences" section for details on possible sample interferences.

Stability[17]	7 days at 20-25 °C 7 days at 4-8 °C 2 months at -20 °C (± 5 °C)

Freeze only once.

Test procedure

The product is ready for use.

For optimum performance of the assay, follow the instructions given in this document for the corresponding analyzer. For analyzer-specific assay instructions, refer to the corresponding User Guide.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma

cobas c 701/702 **test definition**			
Assay type	Rate A		
Reaction time / Assay points	10 / 24-38		
Wavelength (sub/main)	480/450 nm		
Reaction direction	Increase		
Units	U/L (µkat/L)		
Reagent pipetting		Diluent (H_2O)	
R1	75 µL	25 µL	
R3	17 µL	21 µL	
Sample volumes	*Sample*	*Sample dilution*	
		Sample	*Diluent (NaCl)*
Normal	2.8 µL	–	–
Decreased	2.8 µL	20 µL	80 µL
Increased	5.6 µL	–	–

Calculation

The **cobas** c systems automatically calculate the analyte concentration of each sample.

ALP2

Alkaline Phosphatase acc. to IFCC Gen.2

Conversion factor: U/L × 0.0167 = µkat/L

Limitations and interferences

Criterion: recovery within ± 10 U/L of initial values for samples ≤ 100 U/L and within ± 10 % for samples > 100 U/L.

Icterus:[18] no significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:[18] no significant interference up to an H index of 200 (approximate hemoglobin concentration: 124 µmol/L or 200 mg/dL).

Lipemia (Intralipid):[18] no significant interference up to an L index of 2000. There is poor correlation between the L index (corresponds to turbidity) and the triglycerides concentration.

Drugs: No interference was found at therapeutic concentrations using common drug panels.[19,20]

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.[21]

For diagnostic purposes, always assess the results in conjunction with the patient's medical history, clinical examination, and other findings.

Action required

Special wash programming: The use of special wash steps is mandatory when certain test combinations are run together on **cobas** c systems. All special wash programming necessary for avoiding carryover is available via **cobas** link. In certain cases, manual input is required. The latest version of the carryover evasion list can be found on the NaOHD - SMS - SmpCln1+2 - SCCS Method Sheet. For further instructions, refer to the User Guide.

Where required, special wash / carryover evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

5-1200 U/L (0.084-20.0 µkat/L)

Determine samples having higher activities via the rerun function. Dilution of samples via the rerun function is a 1:5 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 5.

Lower limits of measurement

Lower detection limit of the test:

5 U/L (0.084 µkat/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from 0. The lower detection limit is calculated as the value lying 3 standard deviations above the value of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Values below the lower detection limit (< 5 U/L) will not be flagged by the instrument.

Expected values

(measured at 37 °C)

Adults[22]		
Males (n = 221)	40-129 U/L	(0.67-2.15 µkat/L)
Females (n = 229)	35-104 U/L	(0.58-1.74 µkat/L)

Children[23]		
Males		
Age		
0-14 days	83-248 U/L	(1.39-4.14 µkat/L)
15 days-< 1 year	122-469 U/L	(2.04-7.83 µkat/L)
1-< 10 years	142-335 U/L	(2.37-5.59 µkat/L)
10-< 13 years	129-417 U/L	(2.15-6.96 µkat/L)
13-< 15 years	116-468 U/L	(1.94-7.82 µkat/L)
15-< 17 years	82-331 U/L	(1.37-5.53 µkat/L)
17-< 19 years	55-149 U/L	(0.92-2.49 µkat/L)
Females		
Age		
0-14 days	83-248 U/L	(1.39-4.14 µkat/L)
15 days-< 1 year	122-469 U/L	(2.04-7.83 µkat/L)

1-< 10 years	142-335 U/L	(2.37-5.59 µkat/L)
10-< 13 years	129-417 U/L	(2.15-6.96 µkat/L)
13-< 15 years	57-254 U/L	(0.95-4.24 µkat/L)
15-< 17 years	50-117 U/L	(0.84-1.95 µkat/L)
17-< 19 years	45-87 U/L	(0.75-1.45 µkat/L)

Each laboratory is advised to investigate the transferability of the expected values to its own patient population and, if necessary, to determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers is given below. Results obtained in individual laboratories may differ from the representative performance data.

Precision

Precision was determined using human samples and controls based on an internal protocol, with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained on the **cobas** c 701 analyzer:

Repeatability	Mean U/L (µkat/L)	SD U/L (µkat/L)	CV %
Precinorm U	84.3 (1.41)	0.6 (0.01)	0.7
Precipath U	222 (3.70)	1 (0.02)	0.5
Human serum A	52.6 (0.88)	0.5 (0.01)	1.0
Human serum B	160 (2.66)	1 (0.02)	0.6
Human serum C	966 (16.1)	3 (0.1)	0.3

Intermediate precision	Mean U/L (µkat/L)	SD U/L (µkat/L)	CV %
Precinorm U	92.8 (1.56)	2.2 (0.04)	2.4
Precipath U	224 (3.74)	4 (0.06)	1.7
Human serum 3	82.2 (1.37)	1.8 (0.03)	2.1
Human serum 4	1025 (17.1)	9 (0.2)	0.9

Results for intermediate precision were obtained on the **cobas** c 501 analyzer.

The data obtained on the **cobas** c 501 analyzer are representative for the **cobas** c 701 analyzer.

Method comparison

Alkaline phosphatase values for human serum and plasma samples obtained on a **cobas** c 701 analyzer (y) were compared with those determined using the corresponding reagent on a **cobas** c 501 analyzer (x).

Sample size (n) = 73

Passing/Bablok[24]	Linear regression
y = 1.0x – 1.0 U/L	y = 0.999x – 1.6 U/L
τ = 0.991	r = 1.0

The sample activities were between 52 and 1089 U/L (0.87 and 18.2 µkat/L).

Additional information

Additions, deletions, or changes are indicated by a change bar in the margin.

A point (period/stop) is always used in the English version of a Method Sheet as the decimal separator to mark the boundary between the integral and the fractional parts of a decimal numeral. The translated Method Sheets and monolingual labels use decimal commas. Screenshots and multilingual labels only use the decimal point as separator. Separators for thousands are not used.

Report any serious incident that has occurred in relation to the device to the manufacturer and the competent authority of the member state in which the user and/or patient is established.

Symbols

In addition to the ISO 15223-1 standard, Roche Diagnostics uses the following symbols and signs:

ALP2

Alkaline Phosphatase acc. to IFCC Gen.2

CONTENT	Contents of kit
→	Volume for reconstitution
GTIN	Global Trade Item Number
Rx only	For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

References

1 Fraser WD, Alter DN. Bone and mineral metabolism. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, editors. Tietz Textbook of Laboratory Medicine, Saunders Elsevier, Philadelphia, 7th edition, 2023, chapter 54, p. 766-766.e85.

2 Panteghini M. Serum Enzymes. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, editors. Tietz Textbook of Laboratory Medicine, Saunders Elsevier, Philadelphia, 7th edition, 2023, chapter 32, p. 350-350.e36.

3 Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017 Jan;112(1):18-35. doi: 10.1038/ajg.2016.517.

4 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009 Aug;51(2):237-267.

5 Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018 Jan;67(1):6-19. doi: 10.1136/gutjnl-2017-314924.

6 Singer FR, Bone HG 3rd, Hosking DJ, et al. Endocrine Society. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014 Dec;99(12):4408-4422.

7 Vlot MC, den Heijer M, de Jongh RT, et al. Clinical utility of bone markers in various diseases. Bone 2018 Sep;114:215-225.

8 Tan A, Goodman K, Walker A, et al. PRISM-EZ Trial Group. Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study. J Bone Miner Res 2017 Jun;32(6):1165-1173.

9 Thacher TD, Smith L, Fischer PR, et al. Optimal Dose of Calcium for Treatment of Nutritional Rickets: A Randomized Controlled Trial. J Bone Miner Res 2016 Nov;31(11):2024-2031.

10 Makris K, Mousa C, Cavalier E. Alkaline Phosphatases: Biochemistry, Functions, and Measurement. Calcif Tissue Int 2023 Feb;112(2):233-242.

11 King EJ, Armstrong AR. A convenient method for determining serum and bile phosphatase activity. Can Med Assoc J 1934 Oct;31(4):376-381.

12 Ohmori Y. Über die phosphomonoesterase. Enzymologia 1937;4:217-231.

13 Bessey OA, Lowry OH, Brock MJ. A method for the rapid determination of alkaline phosphatase with five cubic millimeters of serum. J Biol Chem 1946 Jul;164:321-329.

14 Hausamen TU, Helger R, Rick W, et al. Optimal conditions for the determination of serum alkaline phosphatase by a new kinetic method. Clin Chim Acta 1967;15:241-245.

15 Schumann G, Klauke R, Canalias F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37° C. - Part 9. Reference procedure for the measurement of catalytic concentration of alkaline phosphatase. Clin Chem Lab Med 2011 Sep;49 (9):1439-1446.

16 Collier BB, Brandon WC, Chappell MR, et al. Maximizing Microsampling: Measurement of Comprehesnive Metabolic and Lipid Panels Using a Novel Capillary Blood Collection Device. JALM 2023 Nov;8(6):1115-1126.

17 Guder WG, Narayanan S, Wisser H, et al. List of Analytes; Preanalytical Variables. Brochure in: Samples: From the Patient to the Laboratory. Darmstadt: GIT-Verlag 1996.

18 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.

19 Breuer J. Report on the Symposium “Drug effects in Clinical Chemistry Methods”. Eur J Clin Chem Clin Biochem 1996;34:385-386.

20 Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

21 Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.

22 Abicht K, El-Samalouti V, Junge W, et al. Multicenter evaluation of new GGT and ALP reagents with new reference standardization and determination of 37 °C reference intervals. Clin Chem Lab Med 2001;39:Special Supplement pp S 346.

23 Estey MP, Cohen AH, Colantonio DA, et al. CLSI-based transference of the CALIPER database of pediatric reference intervals from Abbott to Beckman, Ortho, Roche and Siemens Clinical Chemistry Assays: Direct validation using reference samples from the CALIPER cohort. Clin Biochem 2013;46:1197-1219.

24 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem. 1988 Nov;26(11):783-790.

ALP2

Alkaline Phosphatase acc. to IFCC Gen.2

CE 0123

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany
www.roche.com
+800 5505 6606

Change log

For this document version only:

Due to technical reasons, changes that have been made since the last version of this document are listed in the following table instead of indicated by change bars in the margin.

Section headers are indicated in bold letters.

In addition to the changes listed in the table below, this method sheet version contains several editorial and layout updates.

Section	Current version	Previous version
Materials provided	**Materials provided**	**Order information** **Materials provided**
Materials provided	**Materials provided** without System-ID	**Order information** with System-ID
Materials required (but not provided)	**Materials required (but not provided)**	**Order information** **Materials required (but not provided)**
Materials required (but not provided)	outphased: REF 12149435122 Precinorm U plus REF 12149443122 Precipath U plus	with: REF 12149435122 Precinorm U plus REF 12149443122 Precipath U plus
Reagents	**Reagents**	**Reagents - working solutions**
Warnings and precautions	**Warnings and precautions**	**Precautions and warnings**
Warnings and precautions	laboratory	health care
Specimen collection and preparation	Specimens derived from capillary blood were found acceptable. [Collier BB et al.]	
Test procedure	**Test procedure**	**Reagent handling** **Assay**
Limitations and interferences	**Limitations and interferences**	**Limitations - interference**
Additional information	**Additional information**	
Additional information	A point (period/stop) is always used in the English version of a Method Sheet as the decimal separator to mark the boundary between the integral and the fractional parts of a decimal numeral. The translated Method Sheets use decimal commas. Labels only use the decimal point as separator. Separators for thousands are not used.	A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.
References	Collier BB, Brandon WC, Chappell MR, et al. Maximizing Microsampling: Measurement of Comprehesnive Metabolic and Lipid Panels Using a Novel Capillary Blood Collection Device. JALM 2023 Nov;8(6):1115-1126.	